Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080495 | 0.80 | STS (0.49) | STSPARP1TSHRLMNAALDH1A1 | |
| SCHEMBL17293254 | 0.79 | STS (0.48) | STSMAPT | |
| SCHEMBL22606389 | 0.79 | CXCR2 (0.41) | STSMEN1KMT2A | |
| SCHEMBL12662260 | 0.78 | STS (0.44) | STSMEN1MAPTKMT2A | |
| SCHEMBL22606390 | 0.77 | ELANE (0.36) | LMNA | |
| SCHEMBL2785669 | 0.76 | TGM2 (0.46) | STSMEN1MAPTKMT2A | |
| SCHEMBL19082747 | 0.76 | HSD11B1 (0.39) | STSMAPT | |
| SCHEMBL17293423 | 0.76 | HSD11B1 (0.39) | STSMAPT | |
| SCHEMBL17293424 | 0.76 | HSD11B1 (0.39) | STSMAPT | |
| SCHEMBL17293460 | 0.76 | NAMPT (0.41) | STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388006-A1 | Urea derivatives as IL-8 receptor antagonists | GlaxoSmithKline LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253866-A1 | SWINGING SUPPORT DEVICE | PANASONIC CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| EP-1558259-B1 | Urea derivatives as IL-8 receptor antagonists | GLAXOSMITHKLINE LLC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2203432-A1 | METHOD OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7709485-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
| EP-2032131-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090093492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| EP-1558259-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009039091-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-2032131-A2 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1812008-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007150015-A2 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070249625-A1 | Il-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-10-25 | — | — | US | disclosed |
| EP-1812008-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006043950-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060040952-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1558259-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004039775-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256157-A1 | METHOD OF TREATMENT | CFTR, CTH, TST | STS 28/4885PARP1 4778/4885TSHR 3015/4885 |
| US-20060040952-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | STS 3208/4885PARP1 4100/4885TSHR 666/4885 |
| US-20070249625-A1 | Il-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | STS 3208/4885PARP1 4100/4885TSHR 666/4885 |
| US-20090093492-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | STS 3208/4885PARP1 4100/4885TSHR 666/4885 |
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | STS 15/4885PARP1 3975/4885TSHR 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.